Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

Reviews on Recent Clinical Trials, published by Bentham Science Publishers Ltd, is a distinguished journal in the medical and pharmacological fields, assessing the latest advancements in clinical research since its inception in 2006. With a focus on integrating multidisciplinary approaches to evaluating clinical trial methodologies, the journal caters to a diverse audience of researchers, professionals, and students keen on enhancing their knowledge and understanding of innovative therapeutic strategies and drug developments. Notably positioned in the Q3 quartile as ranked by Scopus for both 'Medicine (miscellaneous)' and 'Pharmacology', the journal illustrates a growing academic influence, evidenced by its Scopus rankings—holding a commendable 72nd percentile in general medicine and a 33rd percentile in pharmacology. While the journal is not open access, it remains committed to disseminating high-quality, peer-reviewed content that drives forward the conversation in clinical research. For those interested in staying abreast of novel findings and comprehensive reviews within the clinical trial landscape, Reviews on Recent Clinical Trials stands out as an essential resource.

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

The Journal of Aerosol Medicine and Pulmonary Drug Delivery, published by MARY ANN LIEBERT, INC, is a distinguished journal dedicated to advancing the field of aerosol medicine and pharmacology. With an ISSN of 1941-2711 and E-ISSN 1941-2703, the journal has established itself as an essential resource for researchers and professionals specializing in pharmaceutical sciences and pulmonary medicine. Ranking in the Q2 category across multiple disciplines, including Pharmaceutical Science and Pulmonary and Respiratory Medicine, it holds notable Scopus rankings, with a percentile of 78th in Pulmonary and Respiratory Medicine. The journal offers open access options, ensuring that cutting-edge research is readily available to a global audience. With converged years from 2008 to 2024, the Journal of Aerosol Medicine and Pulmonary Drug Delivery continues to serve as a vital platform for disseminating innovative research findings, clinical practice insights, and technological advancements in drug delivery systems, thereby significantly impacting therapeutic strategies for respiratory diseases.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.

Welcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.

ANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.